About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

Dr. Ben brings more than 25 years of experience in oncology drug development to leadership team, and will oversee all aspects of BBOT’s clinical development

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer. In this new role, Dr. Ben will oversee BBOT’s ongoing clinical programs, driving the development and delivery of new therapies for cancer patients. These include BBO-8520, BBO-10203, and BBO-11818.

“Ben is a highly accomplished leader with an outstanding record in drug development,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “His extensive experience in accelerating the development of innovative cancer therapeutics will be invaluable as we advance our clinical programs. We are thrilled to have him join our team and look forward to working together to bring new treatments to patients in need.”

Dr. Ben joined BBOT in September 2024, bringing more than 25 years of experience in research and development across the entire life cycle of drug development, from early- to late-stage and through commercialization. He has been instrumental in the approval of more than 10 molecules in more than 20 indications, covering various modalities including small molecules, biologics, and antibody-drug conjugates (ADCs).

Prior to joining BBOT, Dr. Ben was a Venture Partner at Eight Roads Venture, a venture capital firm backed by Fidelity, and served as acting Chief Executive Officer of AlphaGen, a radiopharmaceutical biotech incubated by ERVC and F-Prime Capital. His previous roles include Chief Medical Officer, solid tumors, at BeiGene from 2019 to 2022, and Chief Medical Officer at BioAtla from 2017 to 2019. At AstraZeneca, Dr. Ben was the Global Clinical Leader of Immuno-Oncology Clinical Development, where he led the approval of IMFINZI® (durvalumab) in urothelial cancer. His career highlights also include the approval of NINLARO® (ixazomib) in multiple myeloma at Millennium Pharmaceuticals and INLYTA® (axitinib) in renal cancer at Pfizer. He also currently sits on the board at Corbus Pharmaceuticals.

Dr. Ben began his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. He holds a medical degree from Norman Bethune College of Medicine, and an MBA from the University of California, San Diego.

“I am excited to join Eli Wallace and the talented team at BBOT,” said Dr. Ben. “BridgeBio Oncology Therapeutics is the perfect setting to apply my experience in drug development to accelerate new, meaningful therapeutics to patients afflicted with cancer. I look forward to contributing to the advancement of our clinical programs and making a significant impact on patient care.”

About TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information visit bridgebiooncology.com.

Contacts

BridgeBio Oncology Therapeutics (BBOT) Contact:

Idan Elmelech

Senior Vice President, Strategy & Business Development

contact@bridgebiooncology.com

(650) 405-7021

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.